Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent

1995 ◽  
Vol 131 (2) ◽  
pp. 202-206 ◽  
Author(s):  
G. C. Zimmerman
Keyword(s):  
Chemotherapeutic Agent ◽  
Cutaneous Reactions

scholarly journals Insect bite like rash induced by bendamustine – A common presentation with an uncommon cause

2020 ◽  
Vol 11 (e) ◽  
pp. e152.1-e152.5
Author(s):  
Shibani Bhatia ◽  
Ananth Pai ◽  
Raghavendra Rao ◽  
Srilatha Parampalli Srinivas ◽  
Varsha M Shetty
Keyword(s):  
Chemotherapeutic Agent ◽  
Cutaneous Side Effects ◽  
Common Presentation ◽  
Drug Eruptions ◽  
Johnson Syndrome ◽  
Non Hodgkins Lymphoma ◽  
Cutaneous Reactions ◽  
Steven Johnson Syndrome ◽  
Systemic Symptoms ◽  
Favorable Side Effect Profile

Bendamustine has become a popular cancer chemotherapeutic agent in the last couple of years. It has replaced some traditional chemotherapy regimens due to its favorable side effect profile. Various cutaneous side effects have been noted following bendamustine usage. These cutaneous eruptions are to known to occur in 15-24% of patients. Benign cutaneous events include lichenoid drug eruptions, flagellate dermatoses and polymorphic papules and plaques in exposed areas. Rarely, severe adverse cutaneous reactions such as Steven Johnson syndrome, drug rash with eosinophilia and systemic symptoms and toxic epidermal necrolysis have been reported. We report a case of a 48 year-old-female who developed an insect bite like rash after initiation of bendamustine for non-Hodgkins lymphoma.

The Therapeutic and Diagnostic Value of Fluorine

2020 ◽  
Vol 4 (1) ◽  
pp. 17-29
Author(s):  
Isma Attique ◽  
Shabbir Hussain ◽  
Muhammad Amjad ◽  
Khalida Nazir ◽  
Muhammad Shahid Nazir
Keyword(s):  
Anticancer Agent ◽  
Chemotherapeutic Agent ◽  
Functional Materials ◽  
Diagnostic Value ◽  
Vital Role ◽  
Malignant Growth ◽  
Medical Field ◽  
Active Nucleus ◽  
Broad Application ◽  
Tracer Atom

Fluorine has a useful positron transmitting isotope and it enjoys broad application in the medical field. It is utilized in fluorinated agents,therapeutic sciences and steroid field. Fluorine incorporation viafluoroalkylation is a useful approach in the development of new functional materials and in drug design. Fluorine also plays its role as an anticancer agent and is a successful chemotherapeutic agent for certain sorts of malignant growth. 5-fluorouracil plays a vital role in the treatment of cancer. 18 Facts as a radio label tracer atom in PET imaging. 19 F has the second most sensitive and stable NMR-active nucleus.

Anticancer Hybrid Combinations: Mechanisms of Action, Implications and Future Perspectives

2019 ◽  
Vol 24 (36) ◽  
pp. 4312-4333 ◽  
Author(s):  
Eva M. Domínguez-Martín ◽  
Ana M. Díaz-Lanza ◽  
Célia M. C. Faustino
Keyword(s):  
Paradigm Shift ◽  
Molecular Level ◽  
Chemotherapeutic Agent ◽  
Synergistic Effects ◽  
Extensive Literature ◽  
Synergistic Interactions ◽  
Extensive Literature Search ◽  
Preclinical And Clinical Studies ◽  
Phytochemical Components ◽  
Combination Regimens

The exponential growth of cancer cases worldwide together with recent advances concerning the pathophysiological mechanisms of the disease at the molecular level led to a paradigm shift in chemotherapy, from monotherapy to targeted drug combination regimens. However, adverse effects and the emergence of multidrug resistance (MDR) limit the effectiveness of these therapies. In this context, hybrid combinations mixing anticancer drugs and bioactive phytochemical components from medicinal plants, or even plant extracts, that can act synergistically on multiple targets and signaling pathways represent a promising approach with the potential to expand the current therapeutic arsenal. This review aims to provide a synopsis on anticancer hybrid combinations based on their multi-target mechanisms and synergistic effects from an extensive literature search focusing mainly on publications from the last ten years. In most of these combinations, the phytochemical component was shown to enhance the anticancer activity of the chemotherapeutic agent and to sensitize chemoresistant tumors in several types of cancer. Hybrid combinations, due to synergistic interactions, are also associated with less severe adverse events since lower doses can be used to achieve the same therapeutic effect. Further preclinical and clinical studies are needed, as well as the development of an adequate regulatory framework, before hybrid combination therapy can be translated into clinical practice.

Sign in / Sign up

Export Citation Format

Share Document